Journal article

Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]

Vasso Apostolopoulos, Geoffrey A Pietersz, Anastasios Tsibanis, Annivas Tsikkinis, Heleni Drakaki, Bruce E Loveland, Sara J Piddlesden, Magdalena Plebanski, Dodie S Pouniotis, Michael N Alexis, Ian F McKenzie, Stamatis Vassilaros

BREAST CANCER RESEARCH | BIOMED CENTRAL LTD | Published : 2006

Abstract

INTRODUCTION: Mucin 1 (MUC1) is a high molecular weight glycoprotein overexpressed on adenocarcinoma cells and is a target for immunotherapy protocols. To date, clinical trials against MUC1 have included advanced cancer patients. Herein, we report a trial using early stage breast cancer patients and injection of oxidized mannan-MUC1. METHOD: In a randomized, double-blind study, 31 patients with stage II breast cancer and with no evidence of disease received subcutaneous injections of either placebo or oxidized mannan-MUC1, to immunize against MUC1 and prevent cancer reoccurrence/metastases. Twenty-eight patients received the full course of injections of either oxidized mannan-MUC1 or placebo..

View full abstract